Aprea Therapeutics Acquires Atrin Pharmaceuticals
May 16, 2022
Aprea Therapeutics, Inc. completed a stock-for-stock acquisition of privately held Atrin Pharmaceuticals, obtaining Atrin’s DNA damage response (DDR) oncology programs and proprietary discovery platform. The transaction expands Aprea’s pipeline (including ATRN-119, ATRN-354 and ATRN-W1051), adds Atrin leadership to Aprea’s management and board, and was structured to issue a mix of common stock and Series A preferred stock to former Atrin equity holders (who will own ~58.8% pro forma on an as-converted basis).
- Buyers
- Aprea Therapeutics, Inc.
- Targets
- Atrin Pharmaceuticals Inc.
- Sellers
- Atrin equity holders
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
February 3, 2026
Biotechnology
Cycle Group Holdings Limited, through AT2B, Inc., completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. Applied is a clinical-stage biopharmaceutical company developing govorestat, an aldose reductase inhibitor for CNS rare metabolic diseases.
-
XenoTherapeutics Acquires Repare Therapeutics
January 28, 2026
Biotechnology
XenoTherapeutics, Inc. and Xeno Acquisition Corp. acquired all outstanding shares of Repare Therapeutics Inc. via a statutory plan of arrangement. The deal was approved by Repare shareholders in January 2026 and the acquisition was completed with a per-share cash payment of approximately US$2.20 plus contingent value rights.
-
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics
January 26, 2026
Healthcare Services
BioCryst Pharmaceuticals, Inc. completed its acquisition of Astria Therapeutics, Inc. to strengthen its leadership in hereditary angioedema (HAE) and support long-term growth. The deal adds navenibart, a late-stage long-acting plasma kallikrein inhibitor (Phase 3), and also brings Astria’s early-stage atopic dermatitis program STAR0310 (for strategic alternatives).
-
Recipharm Acquires Arranta Bio
February 18, 2022
Biotechnology
Recipharm has acquired Arranta Bio, a US-based CDMO specializing in advanced therapy medicinal products (ATMPs), microbiome therapeutics and mRNA manufacturing, to expand its biologics and ATMP capabilities and establish a stronger US presence. Arranta Bio brings fermentation, purification, analytics and end-to-end mRNA drug substance and drug product capabilities; the transaction was expected to close around the end of March 2022.
-
APNAR Pharma Acquires Aurex Laboratories
February 3, 2022
Pharmaceuticals
APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.
-
Sorrento Therapeutics Acquires ACEA Therapeutics
June 1, 2021
Biotechnology
Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.